Granted Patent
B2
US 12,414,936 · App. 17/313,562 · Granted Sep 16, 2025
Compositions comprising a serotonergic tryptamine compound
Assignee:
CAAMTECH, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
Claims (5)
1. A dosage composition comprising:
a first purified psilocybin derivative selected from the group consisting of [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N-dimethyltryptamine, 3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3-(2-trimethylaminoethyl)-1H indol-4-yl] dihydrogen phosphate, and 4-hydroxy-N,N,N-trimethyltryptamine; and
a dopaminergic drug.
2. A dosage composition of claim 1 , wherein the dopaminergic drug is selected from the group consisting of amineptine, apomorphine, benzylpiperazine, bromocriptine, cabergoline, chlorpromazine, clozapine, dihydrexidine, domperidone, dopamine, fluphenazine, haloperidol, ketamine, loxapine, methamphetamine, olanzapine, pemoline, perphenazine, pergolide, phencyclidine, phenethylamine, phenmetrazine, pimozide, piribedil, a psychostimulant, reserpine, risperidone, ropinirole, tetrabenazine, and thioridazine.
3. A dosage composition of claim 1 , wherein the first purified psilocybin derivative is [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate or 4-hydroxy-N,N-dimethyltryptamine.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 31, 2025
From: CHADEAYNE, ANDREW R.
To: CAAMTECH, INC.
Reel/Frame 070680/0300 →
Continuity (17)
Provisional Application
62613360
· Jan 3, 2018
Provisional Application
62609115
· Dec 21, 2017
Provisional Application
62598767
· Dec 14, 2017
Provisional Application
62595321
· Dec 6, 2017
Provisional Application
62595336
· Dec 6, 2017
Provisional Application
62593021
· Nov 30, 2017
Provisional Application
62592320
· Nov 29, 2017
Provisional Application
62592307
· Nov 29, 2017
Provisional Application
62587395
· Nov 16, 2017
Provisional Application
62587419
· Nov 16, 2017
Provisional Application
62587410
· Nov 16, 2017
Provisional Application
62587431
· Nov 16, 2017
Provisional Application
62457123
· Feb 9, 2017
References Cited (105)
US 3192111A
· Hofmann et al.
· 1965
[cited by applicant]
US 6303181B1
· Terranova et al.
· 2001
[cited by applicant]
US 6306181B1
· Terranova et al.
· 2001
[cited by applicant]
US 8859579B2
· Sewell
· 2014
[cited by applicant]
US 20040034106A1
· Read et al.
· 2004
[cited by applicant]
US 20050137255A1
· Petersen et al.
· 2005
[cited by applicant]
US 20080293695A1
· Bristol et al.
· 2008
[cited by applicant]
US 20150320814A1
· Patel et al.
· 2015
[cited by applicant]
US 20160250270A1
· Wendschuh et al.
· 2016
[cited by applicant]
US 20160279073A1
· Donsky et al.
· 2016
[cited by applicant]
US 20180021326A1
· Stamets
· 2018
[cited by applicant]
US 20190142851A1
· Chadeayne
· 2019
[cited by applicant]
US 20200375967A1
· Stamets
· 2020
[cited by applicant]
US 20210069170A1
· Stamets
· 2021
[cited by applicant]
GB 2571696B
· 2019
[cited by applicant]
WO 2015127556A1
· 2015
[cited by applicant]
WO 2018135943A1
· 2018
[cited by applicant]
WO 2022038299A1
· 2022
[cited by applicant]
Ebersole et al., “Molecular Basis of Partial Agonism: Orientation of Indoleamine Ligands in the Binding Pocket of the Human Serotonin 5-HT2A Receptor Determines Relative Efficacy,” Molecular Pharmacology, 2003, vol. 63,…
[cited by applicant]
Kawagishi et al., “Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycella of Hericium erinaceum,” Tetrahedron Letters, 1994, vol. 35, No. 10, pp. 1569-1572 (Year: 1994).
[cited by applicant]
Rafael G. dos Santos et al. “Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.” T…
[cited by applicant]
Dutton, Gail, Field Trip Health's New Psilocybin Research Facility Probes the Secrets of Shrooms, BioSpace, Pub. Feb. 26, 2021, https://www.biospace.com/article/field-trip-health-s-new-psilocybin-research-facility-probe…
[cited by applicant]
Griffiths et al. Journal of Psychopharmacology, 30 (12), 2016; pp. 1181-1197.
[cited by applicant]
Ma et al. Mycology, vol. 1, No. 2, 2010; pp. 92-98.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2018/061385, dated Feb. 1, 2019.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/061385, dated May 28, 2020.
[cited by applicant]
International Search Report in International Application No. PCT/US2018/017710, dated Jul. 9, 2018.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/017710, dated Aug. 22, 2019.
[cited by applicant]
Leung et al. ‘Baeocystin and norbaeocystin: New Analogs of psilocybin from Psilocybe baeocystis’, Journal of Pharmaceutical Sciences, Oct. 1968, vol. 57, pp. 1667-1671; p. 1667, p. 1668.
[cited by applicant]
Daly et al. ‘The Chemorelease of Norepinephrine from Mouse Hearts. Structure-Activity Relationships. I. Sympathomimetic and Related Amines’, Journal of Medicinal Chemistry, May 1966, vol. 9, pp. 273-280; p. 273, p. 279.
[cited by applicant]
Glennon ‘Central serotonin receptors as targets for drug research’, Journal of Medicinal Chemistry, Jan. 1987, vol. 30, pp. 1-12; p. 1, p. 6, p. 7.
[cited by applicant]
Jensen et al. ‘Aeruginascin, a Trimethylammonium Analogue of Psilocybin from the Hallucinogenic Mushroom Inocybe aeruginascens’, Planta Medica, Apr. 28, 2006 (Apr. 28, 2006), vol. 72, pp. 1-3; Abstract.
[cited by applicant]
Pubmed Compound Summary for CID 17868117, ‘2-(4-Hydroxy-1H-indol-3-yl)ethyl-trimethylazanium’, U.S. National Library of Medicine, Dec. 4, 2007 (Dec. 4, 2007), p. 1-12 (https://pubchem.ncbi.nlm.nih.gov/compound/17868117)…
[cited by applicant]
Niels Jensen , “Tryptamines as Ligands and Modulators of the Serotonin 5-HT 2A Receptor and the Isolation of Aeruginascin from the Hallucinogenic Mushroom Inocybe aeruginascens”, Dissertation zur Erlanggun des Doktograd…
[cited by applicant]
El-Aify et al., Pharmacal. Biochem. Behav., 2010, vol. 95, No. 4, apges 434-442 (Year: 201 0).
[cited by applicant]
Vollenweider et al., Nature Reviews Neuroscience, 2010, vol. 11, No. 9, pp. 642-651 (Year: 201 0).
[cited by applicant]
Maione et al., Br. J. Pharmacal., 2011, vol. 162, pp. 584-596 (Year: 2011).
[cited by applicant]
Bigwood, J_ et al., “Variation of Psilocybin and Psilocin Levels with Repeated Flushes (Harvests) of Mature Sporocarps of Psilocybe Cubensis (Earle) Singer,” Journal of Ethnopharmacology, vol. 5 No. 3, pp. 287-291 (1982…
[cited by applicant]
Li, I-Chen et al., “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines,” Behavioural Neurology, vol. 2018, pp. 1-11 (2018).
[cited by applicant]
PsyBio Therapeutics Corp., PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin, Mar. 23, 2021, https://www.newswire.ca/news-releases/psybio-therapeutics-initiates-process-developm…
[cited by applicant]
Gukasyan et al., “Attenuation of Psilocybin Mushroom Effects During and After SSRI-SNRI Antidepressant Use”, Journal of Psychopharmacology, 00(0), 1-10, 2023.
[cited by applicant]
Lane, et al., “Selective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome: Review”, Journal of Clinical Psychopharmacology, 17(3), 208-221, 1997.
[cited by applicant]
Alper (2008) “The ibogaine medical subculture” Journal of Ethnopharmacology. 115(1): 9-24.
[cited by applicant]
“Amount of Niacin in Mushrooms” (http://www.dietandfitnesstoday.com/niacin-in-mushrooms.php; 12 pages) (Accessed Feb. 1, 2022)(Year: 2022).
[cited by applicant]
Barrett (2006) “Patterns of simultaneous polysubstance use in drug using university students” Hum. Psychopharmacol. Clin. Exp. 21: 255-263, Apr. 6, 2006, Human Psychopharmacology Clinical and Experimental.
[cited by applicant]
Becker et al., “Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects,” Clinical Pharmacology & Therapeutics, vol. …
[cited by applicant]
Boys (2001) “Understanding reasons for drug use amongst young people a functional perspective” Health Education Research. 16(4):457-469.
[cited by applicant]
Carhart-Harris et al., “The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future,” Lancet Psychiatry, 2016, vol. 3, pp. 619-627 (Year: 2016).
[cited by applicant]
Chadeayne et al., “Norpsilocin: freebase and fumarate salt,” Acta Crystallogr. E Crystallogr. Commun., Mar. 27, 2020;76(Pt 4) :589-593 (Year: 2020).
[cited by applicant]
Chilton (1979) “Psilocin, Bufotenine and Serotonin: Historical and Biosynthetic Observations” Journal of Psychedelic Drugs. 11(1-2) pp. 61-69, Jan. 1979, Journal of Psychedelic Drugs.
[cited by applicant]
Daniel, J., et al., ‘Clinical potential of psilocybin as a treatment for mental health conditions’, Mental Health Clinician, 2017, vol. 1, p. 24-28.
[cited by applicant]
Fozard (1978) “Dual mechanism of the stimulant action of N,N-dimethyl-5-hydroxytryptamine (bufotenine) on cardiac sympathetic nerves” European Journal of Pharmacology. 49(1):25-30.
[cited by applicant]
Gilman, “Compass Pathways Offers More Proof SSRI Drugs Do No Impede Psilocybin's Therapeutic Effect,” Psychedelic Spotlight, Dec. 13, 2021, https://psychedelicspotlight.com/compass-pathways-study-ssri-drugs-psilocybin-t…
[cited by applicant]
Hanes, K. R., ‘Serotonin, Psilocybin, and Body Dysmorphic Disorder: A Case Report’, Journal of Clinical Psychopharmacology, 1996, vol. 16(2), p. 188-189.
[cited by applicant]
Kasper et al. “Silexan in anxiety disorders: Clinical data and pharmacological background,” The World Journal of Biological Psychiatry, 2018, 19:6, pp. 412-420 (Published Online Jun. 19, 2017) (Year:2018).
[cited by applicant]
Leeann, “Personal Story: Iboga And Psilocybin Mushrooms Saved Me On The Brink Of Suicide” Mar. 16, 2015; retrieved from Web Archive, Resethttps://web.archive.org/web/20151203193 708/https://reset.me/personal-story/perso…
[cited by applicant]
Lenz et al. “Identification of w-N-Methyl-4-hydroxytryptamine (Norpsilocin) as a Psilocybe Natural Product”, J. Nat. Prod., 2017, vol. 80, pp. 2835-2838 (Year: 2017).
[cited by applicant]
Licht (2012) “Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposedbiological bases” Hum. Psychopharmacol. Clin. Exp. 27: 352-363.
[cited by applicant]
Mahmood “Bioactive Alkaloids from Fungi: Psilocybin”, Chapter 18 in book Natural Products, K.G. Ramawat, J.M. Merillon (eds.),2013, pp. 523-552 (Year: 2013).
[cited by applicant]
Matsushima et al., “Historical overview of psychoactive mushrooms”, Inflammation and Regeneration, 2009, pp. 47-58, 29(1).
[cited by applicant]
Nichols et al. “Psychedelics as Medicines: An Emerging New Paradigm”, Clinical Pharmacology & Therapeutics, Feb. 2017, vol. 101, No. 2, pp. 209-219 (Year: 2017).
[cited by applicant]
Ott (1999) “Human Pharmacology of Oral DMT Plus Harmine” Journal of Psychoactive Drugs.31(2):171-177.
[cited by applicant]
Quednow, B. B, et al., ‘Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers’, Neuropsychopharmacology, 2012, vol. 37, p. 630-640.
[cited by applicant]
Rambousek et al., “The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat”, Front. Behav. Neurosci., 2014, 8(180).
[cited by applicant]
Ross et al., “Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial”, Journal of Psychopharmacology, 2016…
[cited by applicant]
Russo, “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,” (British Journal of Pharmacology, 2011, vol. 163, pp. 1344-1364) (Year: 2011).
[cited by applicant]
Sard et al. “SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist”, . Bioorg Med Chem Lett., 2005, pp. 4555-4559, 15(20).
[cited by applicant]
Sanchez “Bioactives from Mushroom and Their Application” (2017) in book Food Bioactives, M. Puri (ed), pp. 23-57) (Year:2017).
[cited by applicant]
Schechter (1998) “Candyflipping': Synergistic discriminative effect of LSD and MDMA” European Journal of Pharmacology. 314: 131-134.
[cited by applicant]
Schuwald et al., “Lavender Oil-Potent Anxiolytic Properties via Modulating Voltage Dependent Calcium Channels,” PLoS ONE, 2013, vol. 8, No. 4, e59998, doi: 10.1371/journal.pone.0059998, 9 pages (Year: 2013).
[cited by applicant]
Sessa (2015) “Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary” Drug Science, Policy andLaw. 2(0):1-8.
[cited by applicant]
Shelton (2005) “Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance” J. Clin. Psychiatry. 66(10): 1289-1297.
[cited by applicant]
Sherwood et al. “Synthesis and Biological Evaluation ofTryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin,Baeocystin, Norpsilocin, and Aeruginascin”, J. Nat. Prod., 2020, vol. 83, pp. 461-467 (Year: 2020).
[cited by applicant]
Shroomery, “Re: LSA and Shrooms [Re: MycoKris]” 2006; retrieved from https://www.shroomery.org/forums/showflat.php/Number/60334 73#60334 73, retrieved Sep. 5, 2006.
[cited by applicant]
Shulgin (1997) Tihkal: Tryptamines I Have Known And Loved: The Chemistry Continues, Chapter 48 line 256-261, 1997, Transform Press ISBN:0-9630096-9-9.
[cited by applicant]
Stebelska, “Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol: Analytical Methods and Biologic Activities”, Ther Drug Monit., 2013, pp. 420-442, 35(4).
[cited by applicant]
Szegedi (1996) “Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data” J. Clin. Psychiatry. 57(6):257-264.
[cited by applicant]
Thomas et al., “Combination Therapy with Monoamine Oxidase Inhibitors and Other Antidepressants or Stimulants: Strategies for the Management of Treatment-Resistant Depression,” Pharmacotherapy, 2015, vol. 35, No. 4, pp.…
[cited by applicant]
Tittarelli (2015) “Recreational Use, Analysis and Toxicity of Tryptamines” Current Neuropharmacology. 13: 26-46.
[cited by applicant]
Tyls et al., “Psilocybin—summary of knowledge and new perspectives”, Eur Neuropsychopharmacol, 2014, pp. 342-356, 24(3).
[cited by applicant]
White, “Mixing DXM and Other Drugs” 2015; retrieved from Web Archive, Erowid. https://web.archive.org/web/20150422070624/https://www .erowid.org/chemicals/dxm/faq/dxm_mixing.shtml, retrieved Apr. 22, 2015.
[cited by applicant]
Wink, “Modes of Action of Herbal Medicines and Plant Secondary Metabolites,” (Medicines, 2015, vol. 2, pp. 251-286) (Year: 2015).
[cited by applicant]
Zhuk et al., “Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice”, Toxins, 2015, pp. 1018-1029, 7(4).
[cited by applicant]
Bauer, “Scientists Synthesize and Test the Magic Mushroom Compounds Baeocystin, Norbaeocystin, Norpsilocin, and Aeruginascin,” Psychedelic Science Review, Mar. 5, 2020, https://psychedelicreview.com/scientists-synthesiz…
[cited by applicant]
Carhart-Harris et al., “The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future,” Neuropsychopharmacology, 2017, vol. 42, pp. 2105-2113 (Published Online May 17, 2017) (Year: 2017).
[cited by applicant]
Shirota et al., “Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of Magic Mushrooms”, J. Nat. Prod., 2003, vol. 66, pp. 885-887 (Year: 2003).
[cited by applicant]
Carhart-Harris et al., “Psilocybin with Psychological Support for Treatment-Resistant Depression: an open-label feasibility study,” Lancet Psychiatry, 2016, vol. 3, pp. 619-627 (Year: 2016).
[cited by applicant]
Chen et al., “Chemistry of Chinese Edible and Medicinal Fungi,” Shanghai Science and Technology Press, 2016, ISBN: 978-7-5439-6915-5.
[cited by applicant]
Dörner et al., “Genetic survey on Psilocybe natural products,” Wiley-VCH, pp. 1-8, 2022.
[cited by applicant]
Du Xiu-ju et al, Muchroom Toxins and Present Research of Its Utilization, Journal of Anhul Agri Sci, 2010,38 (13) : 7172-7174.
[cited by applicant]
Health Canada, Notice to Stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP), Government of Canada, May 6, 2…
[cited by applicant]
Stamets at al. Psilocybin Mushrooms of the World: An Identification Guide. First Edition. Berkeley, Calif: Ten Speed Press; 1996.
[cited by applicant]
Yamada et al. (Chem. Pharm. Bull, 2002, vol. 50, No. 1, p. 92-99) (Year: 2002).
[cited by applicant]